APP Pharma expands Grand Island manufacturing plant
APP Pharma, a wholly subsidiary of Fresenius Kabi Pharmaceuticals, has further added six production lines for injectable products in the plant. At its Grand Island facility, the company
Amgen has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for Repatha (evolocumab) supporting its broader use prior to a first heart attack or stroke.